CIK 0001520262 · Large accelerated filer
Alkermes plc.
Sign in to watch- Ticker
- ALKS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 981007018
- Phone
- 00-353-1-772-8000
- Business address
- CONNAUGHT HOUSE, 1 BURLINGTON ROAD, DUBLIN 4, Ireland, 00000
- Former names
- ANTLER SCIENCE TWO PLC, Antler Science Two Ltd
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,070,874
- in 5 filings, $1.1M under 10b5-1 plans
Net −$1,070,874. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-02-12 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | Option exercise · Employee Stock Option (Right to Buy) 10b5-1 | −87,566 | 0 | ||
| 2025-02-12 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | Option exercise · Employee Stock Option (Right to Buy) 10b5-1 | −111,630 | 50,104 | ||
| 2025-02-06 | POPS RICHARD F Director and CEO, Alkermes plc | Grant or award | +190,640 | 1,370,315 | ||
| 2025-02-06 | POPS RICHARD F Director and CEO, Alkermes plc | Shares withheld for taxes | −79,925 | $31.39 | $2.5M | 1,290,390 |
| 2025-02-06 | Nichols Christian Todd SVP, Chief Commercial Officer | Grant or award | +24,565 | 85,268 | ||
| 2025-02-06 | Nichols Christian Todd SVP, Chief Commercial Officer | Shares withheld for taxes | −7,399 | $31.39 | $232K | 77,869 |
| 2025-02-06 | Jackson Blair Curtis EVP, Chief Operating Officer | Grant or award | +34,393 | 192,195 | ||
| 2025-02-06 | Jackson Blair Curtis EVP, Chief Operating Officer | Shares withheld for taxes | −10,647 | $31.39 | $334K | 181,548 |
| 2025-02-06 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | Grant or award | +34,393 | 78,683 | ||
| 2025-02-06 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | Shares withheld for taxes | −15,083 | $31.39 | $473K | 63,600 |
| 2025-02-06 | Gaffin David Joseph EVP, CLO, Alkermes, Inc. | Grant or award | +32,350 | 198,251 | ||
| 2025-02-06 | Gaffin David Joseph EVP, CLO, Alkermes, Inc. | Shares withheld for taxes | −9,752 | $31.39 | $306K | 188,499 |
| 2025-02-06 | Brown Iain Michael SVP, Chief Financial Officer | Grant or award | +24,565 | 140,909 | ||
| 2025-02-06 | Brown Iain Michael SVP, Chief Financial Officer | Shares withheld for taxes | −7,514 | $31.39 | $236K | 133,395 |
| 2025-01-30 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | Option exercise 10b5-1 | +29,156 | $20.03 | $584K | 76,732 |
| 2025-01-30 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | Option exercise 10b5-1 | +26,589 | $19.34 | $514K | 103,321 |
| 2025-01-30 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | Option exercise 10b5-1 | +23,542 | $24.59 | $579K | 126,863 |
| 2025-01-30 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | Option exercise 10b5-1 | +18,345 | $26.82 | $492K | 145,208 |
| 2025-01-30 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | Sale 10b5-1 | −100,918 | $32.05 | $3.2M | 44,290 |
| 2025-01-30 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | Option exercise · Employee Stock Option (Right to Buy) 10b5-1 | −29,156 | 87,566 |
Page 19 of 41 · 804 trades